Clinical progression predictions are now indication-specific, led by an easy-to-read percentile rank instead of a raw probability, with a redesigned Clinical Landscape chart showing exactly where each target-disease pairing stands, phase by phase.
This release makes Target Intelligence’s clinical progression predictions sharper and dramatically easier to trust at a glance.
New: Indication-Specific Predictions
Clinical progression scores are no longer a single number for a gene — they’re now specific to the exact disease you’re evaluating. Ask about a target for one indication and get a prediction built for that pairing, not a generic average across everything the gene has ever been studied for.
New: Percentile Rank Replaces Raw Probability
Instead of a raw probability that could look alarmingly low even for a target with an approved drug already on the market, every prediction now leads with a percentile rank — “this pairing ranks in the top 10% of everything the model has seen” — a number you can trust and compare at a glance, phase by phase.
Improved: Clinical Landscape Chart
The Clinical Landscape chart in Target Explorer has been redesigned around this new percentile rank. Pick exactly the indication you care about from a ranked list, and see its own percentile for Phase 1, 2, and 3 trials side by side — no more hunting for the same number repeated across a long, scrolling chart.
Improved: Reports Reflect What You Actually Asked
When you name a specific disease alongside a target, Target Intelligence reports and their clinical-progression charts now reflect that exact disease — not just whichever indication the platform would have guessed on its own.
And as always
We’ve continued hardening the platform’s prediction infrastructure so the numbers you see keep getting more reliable as the product gets more capable.